The influence of pregnancy and menstruation on the deterioration of atopic dermatitis symptoms by 諛뺤갹�슧 et al.
180 Ann Dermatol
Received January 12, 2010, Revised February 10, 2010, Accepted for 
publication February 19, 2010
*This study was supported by a grant of the Korea Health 21 R&D 
Project (Ministry of Health & Welfare and Family Affairs, Republic of 
Korea, A080892).
Corresponding author: Kwang Hoon Lee, M.D., Department of 
Dermatology and Cutaneous Biology Research Institute, Yonsei 
University College of Medicine, 250 Seongsan-ro, Seodaemun-gu, 
Seoul 120-752, Korea. Tel: 82-2-2228-2080, Fax: 82-2-393-9157, 
E-mail: kwanglee@yuhs.ac
Ann Dermatol Vol. 22, No. 2, 2010 DOI: 10.5021/ad.2010.22.2.180
ORIGINAL ARTICLE
The Influence of Pregnancy and Menstruation on 
the Deterioration of Atopic Dermatitis Symptoms
Suhyun Cho, M.D., Hee Jung Kim, M.D.1, Sang Ho Oh, M.D., Chang Ook Park, M.D., 
Jin Young Jung, M.D., Kwang Hoon Lee, M.D.
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 1Department of 
Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Korea
Background: Female patients with atopic dermatitis (AD) 
often experience cutaneous deterioration associated with 
their pregnancy or menstrual cycle. Objective: We wanted to 
determine the prevalence of symptom aggravation as related 
to pregnancy and the menstrual cycle in female patients with 
AD. Methods: One hundred female patients with AD were 
included in the study and interviews were performed. The 
total IgE level and the Eczema Area and Severity Index score 
of the patients were retrospectively reviewed. Results: 
Ninety seven patients replied the questionnaire, and among 
them, 23 patients had completed at least 1 pregnancy. 
Among the 23 women who experienced pregnancy, 14 
(61%) had noticed deterioration of their clinical symptoms 
during pregnancy. Of the 97 females, 31 (32%) patients had 
noticed deterioration of their AD as related to their menstrual 
cycle. For the patients who were sub-grouped as the intrinsic 
type of AD, the prevalence of symptom aggravation as 
related to pregnancy was significantly higher as compared to 
that of the extrinsic type of AD patients (p=0.048). 
Conclusion: Of the 97 patients, 45 (46%) females answered 
that they have experienced deterioration of AD during 
pregnancy or in relation to their menstrual cycle, and this 
suggests the relation of a hormonal influence on the clinical 
manifestations of AD. (Ann Dermatol 22(2) 180∼185, 2010)
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory disease 
with the lifetime prevalence of 8∼17% in adults under 60 
years old and it has a number of subtypes1. Intrinsic AD 
(IAD) is differentiated from the much more common 
extrinsic type (EAD) by a total serum immunoglobulin E 
(IgE) level that is within the normal range, by the lack of 
specific IgE positivities and by the fact that no immediate 
skin reaction to environmental allergens or respiratory 
involvement can be observed2-4. In several previous 
studies, the disease activity of several dermatoses was 
shown to be influenced by hormonal factors in women, 
and AD had a higher prevalence in adult females5,6. 
According to previous studies, approximately 25% of 
females who have AD experience improvement during 
pregnancy, and more than 50% of the AD female patients 
experience deterioration during pregnancy7,8. Moreover, 
female patients with AD often show a deterioration of 
cutaneous symptoms in relation to the menstrual cycle9. 
We have experienced that a number of female patients 
with AD in our clinic have reported their symptoms 
worsened during pregnancy and even in relation to their 
menstrual cycle. However, the influence of pregnancy and 
the menstrual cycle on AD has not been discussed in the 
Korean dermatologic literature. The purpose of this study 
is to investigate the influence of pregnancy and the 
menstrual cycle on the symptoms of AD, which would 
reflect a hormonal influence on AD, and to compare the 
results between the intrinsic and extrinsic types of AD.
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Table 1. The demographics and clinical manifestations of the 
enrolled AD patients
Characteristics AD patients (n=97) (%)
Age [years, mean±SD (range)] 26.3±5.8 (20∼50)
  20∼30 71 (73.2)
  30∼40 23 (23.7)
  40∼50 3 (3.1)
Total IgE [kU/l, mean±SD (range)] 1,007.3±1,295.5
(4.1∼5,000)
Log total IgE 2.5±0.8
EASI score [value, mean±SD (range)] 12.3±10.1
(0.8∼41.7)
  <10 51 (52.6)
  10∼20 29 (29.9)
  20∼30 9 (9.3)
  >30 8 (8.2)
Subtype
  IAD 34 (35.1)
  EAD 63 (64.9)
Experienced at least 1 pregnancy 23 (23.7)
AD: atopic dermatitis, EASI: Eczema Area and Severity Index, 
IAD: intrinsic AD, EAD: extrinsic AD.
MATERIALS AND METHODS
Patients
One hundred female patients with AD who visited the 
Department of Dermatology at Yonsei University Health 
System in Seoul, Korea during January, 2007 to December, 
2008 were included in the study. The diagnosis of AD was 
based on the criteria of Hanifin and Rajka10. The inclusion 
criteria were female AD patients over the age of 20 years 
old who had no other systemic diseases and who had the 
ability to understand and give appropriate answers to the 
questionnaire.
Assessment of the influence of pregnancy and the 
menstrual cycle on AD symptoms
An interview was performed for the 100 female patients. 
The questionnaire included questions about whether the 
patients have experienced deterioration or improvement 
of AD during pregnancy or as related to their menstrual 
cycle, and if they have experienced any changes, which 
period did the change appear during pregnancy or during 
the menstrual cycle was asked. 
The degree of aggravation each patient experienced in 
relation to pregnancy or their menstrual cycle was also 
assessed using a mild-moderate-severe 3 scale grading 
system: mild (＜33% worsening as compared to the 
average cutaneous signs and symptoms before pregnancy), 
moderate (33∼66% worsening) or severe (＞66% wor-
sening). The total IgE levels and the Eczema Area and 
Severity Index (EASI) score were examined on the hospital 
visit and the average values were compared between the 
patient groups (those who have experienced deterioration 
and those who have not experienced any noticeable 
changes). In addition, we classified the patients into those 
who showed low total serum IgE levels (＜200 kU/l), with 
the absence of associated respiratory diseases, a lack of 
allergen specific serum IgE antibodies and negative skin 
prick tests into the intrinsic AD (IAD) group11. We compared 
the difference in the prevalence of symptom aggravation 
in association to pregnancy or menstruation between the 
IAD patients and the extrinsic AD (EAD) patients.
Statistical analysis
All the analyses were performed with the SPSS statistical 
package (SPSS Inc., Chicago, IL, USA). The differences in 
the levels of total IgE and the EASI score between the 
patient groups (those who experienced deterioration and 
those who did not experience any noticeable changes) 
were analyzed with Student’s t-test. The chi-square test 
and Fisher’s exact test were performed in order to 
determine the difference of the prevalence of symptom 
aggravation in association with pregnancy or menstruation 
between the IAD and EAD patients. A p-value ＜0.05 was 
accepted as statistically significant.
RESULTS
Demographic and clinical characteristics of the AD 
patients
Ninety seven of the 100 enrolled patients replied the 
questionnaire. The mean age of the patients was 26.3± 
5.8 years (range: 20∼50 years old). Seventy one (73.2%) 
of patients were in their twenties, 23 (23.7%) were in their 
thirties and 3 (3.1%) were over 40 years old. The mean 
EASI score of the 97 patients was 12.3±10.1 and 51 
patients had EASI scores from 0∼9, 29 had scores from 
10∼19, 9 had scores from 20∼29, and 8 had EASI scores 
higher than 30. Twenty three females had experienced at 
least 1 pregnancy and their mean age was 35.1 years 
(range: 29∼50 years). There were 34 patients who were 
sub-grouped as IAD, and 63 were sub-grouped as EAD 
(Table 1).
Association between pregnancy and aggravation of AD 
symptoms
Among the 23 patients who experienced pregnancy, 15 
(65%) females described a clinical change of their AD 
during pregnancy, with 14 (61%) females who experienced 
deterioration of AD during their pregnancies and 1 (4%) 
who had improvement of symptoms during pregnancy. 
The remaining 8 patients answered that they did not 
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Fig. 2. The influence of pregnancy on the aggravation of AD 
symptoms between the IAD (n=6) and EAD groups (n=17).
Fig. 1. The association between pregnancy and aggravation of AD
symptoms. The changes of AD symptoms associated with 
pregnancy in the AD patients who have experienced at least one
pregnancy (n=23) (A). The degree (B) and period (C) of 
deterioration among the patients who experienced deterioration 
of AD during pregnancy (n=14).
notice any change during pregnancy (Fig. 1A). Of the 14 
patients who experienced deterioration during pregnancy, 
2 (14%) experienced a mild degree, 8 (57%) experienced 
a moderate degree and 4 (29%) experienced a severe 
degree of deterioration (Fig. 1B). Ten patients (71%) 
experienced deterioration during the 2nd or 3rd trimester 
of pregnancy (Fig. 1C). Of the 14 patients who experienced 
symptom aggravation during pregnancy, 6 (42.9%) 
patients were sub-grouped as IAD and 8 (57.1%) were 
sub-grouped as EAD. The patients who did not experience 
any clinical changes of AD during pregnancy and the 1 
female who experienced improvement were all EAD. The 
prevalence of AD symptom aggravation associated with 
pregnancy was significantly higher for the IAD patients as 
compared to that of the EAD patients (6/6, 100% vs 8/17, 
47.1%, p=0.048) (Fig. 2). 
Association between menstruation and the aggravation 
of AD symptoms
A question asking whether the patients have experienced 
any changes of AD as related to their menstrual cycle was 
asked of all 97 females. Thirty one (32%) females experi-
enced deterioration of AD as related to the menstrual 
cycle, and 66 (68%) answered that they have not felt any 
noticeable changes (Fig. 3A). Twenty (64.5%) of the 
patients who experienced deterioration related to the 
menstrual cycle experienced mild worsening (Fig. 3B), 
and 18 (64%) females experienced premenstrual deterioration 
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Fig. 3. The association between menstruation and the aggravation
of AD symptoms. The changes of AD symptoms associated with 
the menstrual cycle in AD patients (n=97) (A). The degree (B) 
and period (C) of deterioration among the patients who 
experienced deterioration of AD in relation to their menstrual 
cycle (n=31).
within about 10 days before menstruation (Fig. 3C). 
Between the patient groups who experienced deterio-
ration related to their menstrual cycle and those who did 
not, any statistical difference of the prevalence of 
symptom aggravation was not noticed between the IAD 
and EAD patients. Among the 23 females with AD and 
who experienced at least 1 pregnancy, 7 females (30.4%) 
were affected by both pregnancy and the menstrual cycle 
(30.4%), and 45 (46%) out of the 97 patients were 
affected by pregnancy or menstruation. 
Comparison of the differences in the total IgE levels 
and the EASI score between the patient group who 
experienced deterioration of symptoms related to 
pregnancy or menstruation, and the patient group who 
did not
The total IgE levels and EASI score was compared 
between the patient group who experienced deterioration 
during pregnancy or as related to the menstrual cycle and 
the patient group who have not experienced any changes. 
The total IgE level and EASI score were measured when 
the questionnaire was filled in. The patients who 
experienced deterioration of AD during pregnancy had a 
mean lower level of total IgE and a mean higher EASI 
score as compared to those values of the patients who 
showed no relationship between pregnancy and AD 
symptoms (904±1,351 vs 1,810.6±1,577.4 and 15.6±10.9 
vs 11±11.2, respectively). The patients who experienced 
deterioration of AD as related to the menstrual cycle had a 
slightly higher mean total IgE level and mean EASI score 
as compared to those values of the patients who have not 
experienced any changes as related to the menstrual cycle 
(1,185.6±1,499.7 vs 923.5±1,191 and 13.4±9.9 vs 
11.7±10.3, respectively). However, the statistical analysis 
did not reveal significant differences. 
DISCUSSION
Although it has long been recognized that female patients 
with AD often show a deterioration of cutaneous symptoms 
in relation to the menstrual cycle, the information about 
this subject is insufficient12,13. A review of the literature 
has revealed great variance in the prevalence of the 
menstrual-cycle-associated worsening of AD skin lesions, 
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ranging from 9% to 100%7,14-18. Yet in the previous studies 
that have examined a comparatively large number of 
patients, the frequency of menstrual cycle-associated 
aggravation of AD skin lesions was estimated to be around 
50∼70%15,18. 
In our study, we found out that 46% of the female AD 
patients have experienced deterioration of symptoms 
during pregnancy or in relation to the menstrual cycle. 
Among the patients who experienced aggravation related 
to the menstrual cycle, 64% experienced deterioration 
before the menstruation and generally within 10 days 
before menstrual initiation. The results suggest that there 
exists a relation between hormonal influences and the 
clinical manifestations of AD. As Kemmett and Tidman7 
reported previously, there might be some association 
between the premenstrual worsening of AD and the 
presence of symptoms of premenstrual syndrome. According 
to a study of Kiriyama et al.9, the physical and 
psychological symptoms of premenstrual syndrome were 
present in all the AD patients who showed premenstrual 
worsening of skin lesions, but these were absent in the 
group of patients who did not show premenstrual skin 
aggravation. Systemic evaluations and further interviews 
of AD patients regarding premenstrual syndrome are 
required to reveal the definite relation.
Most pregnant women are unwilling to use topical and 
systemic treatments, and so discontinuation of medications 
might be a leading cause of aggravation of AD. In our 
study, among the 14 patients who experienced aggravation 
during pregnancy, 10 patients experienced aggravation 
during the 2nd or 3rd trimester, and the 4 patients who 
experienced aggravation during the 1st trimester did not 
use any oral medications for several months prior to 
pregnancy. Therefore, the cessation of medication itself 
independent to pregnancy did not seem to be the major 
cause of AD aggravation. The use of medication by AD 
patients before and after pregnancy should be consistent 
to firmly determine if pregnancy is a deteriorating factor of 
AD. Nevertheless, as the continuation of AD symptoms 
into adulthood, which is when most of females experience 
pregnancy, is not very common, we included all the AD 
patients who experienced pregnancy in our study for the 
purpose of obtaining a large cohort. Therefore, further 
studies are needed with controlled distributable factors to 
clarify the relationship between pregnancy and the 
deterioration of AD symptoms. 
The total IgE levels and EASI score did not show 
statistically significant differences between the patients 
who noticed some deterioration during pregnancy or in 
relation to the menstrual period and the patients who 
were without deterioration of AD symptoms during pre-
gnancy and menstruation. This infers that that worsening 
during pregnancy or in relation to the menstrual cycle is 
not related to the severity of the disease. The degree of the 
premenstrual skin deterioration was different from patient 
to patient, suggesting there are individual differences in 
the susceptibility to the aggravation of AD. These results 
are equivalent with those of the previous studies9. The 
patient group who experienced deterioration during pre-
gnancy or as related to the menstrual cycle had a larger 
portion of patients sub-grouped as IAD, as compared to 
that of the patient group who did not experience any 
changes. This result suggests that, for IAD, the disease can 
be more susceptible to hormonal influences as compared 
to the extrinsic type. In our study, the deterioration of AD 
as related to pregnancy tended to appear at higher rates 
for the IAD patients as compared to that of the EAD 
patients, but the relationship between menstruation and 
symptom aggravation of AD in the IAD or EAD patients 
did not reveal statistically significant differences. These 
results suggest that although IAD patients lack sensiti-
zation by allergens and they do not show aggravation by 
specific allergens, other factors such as hormones or stress 
may have more impact on the clinical manifestations of 
IAD. Further studies are required to investigate the 
susceptibility of hormonal influences in patients with IAD 
and EAD.
It is now known that pregnancy shifts the T cell immunity 
towards a type 2 T helper response, and this is thought to 
be important for continuation of a normal pregnancy19. 
Ikeno and Takahashi20 described that the Dehydroepiand-
rosterone (DHEA) and DHEA-sulphate (DHEA-S) levels, 
which apparently show the immunomodulatory effects 
probably by enhancing Th1 activity21,22, decrease during 
pregnancy20, and this can be one factor that contributes to 
the shift of the immune response to the type 2 helper 
response during pregnancy. As the type 2 T helper 
response is also associated with AD, this shift may explain 
why AD can deteriorate during pregnancy. There is also some 
experimental data suggesting sex hormones have an 
influence on the symptoms of AD, as estrogens were 
shown to affect mast cell activation, while progesterone 
was shown to suppress histamine release, but potentiate 
IgE induction in rodent models6. However, as any actual 
data from human studies is lacking, further investigations 
are required.
The mechanisms still remain obscure for the case of 
deterioration of AD as related to the menstrual cycle. It is 
reported that for females, skin reactivity to irritants and 
antigenic substances increases during the premenstrual 
phase23,24. It is then possible that female patients with AD 
show an exaggerated inflammatory skin response to 
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various aggravating substances in the week prior to men-
struation, leading to the premenstrual deterioration of the 
disease9.
In conclusion, although this study is limited by the small 
number of patients and its retrospective and subjective 
nature, it is valuable because such a study is rare in the 
Korean literature. Our results suggest that there exist a 
relation between hormonal influences and the clinical 
manifestations of AD, and further investigations with 
larger cohorts are needed to clarify the relationship 
between sex hormones and AD.
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